{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:20:21Z","timestamp":1792592421410,"version":"4.5.0"},"reference-count":53,"publisher":"Impact Journals, LLC","issue":"90","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,11,16]]},"DOI":"10.18632\/oncotarget.26333","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T09:14:56Z","timestamp":1542359696000},"page":"36220-36237","source":"Crossref","is-referenced-by-count":32,"title":["The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension"],"prefix":"10.18632","volume":"9","author":[{"given":"Frank Erhard","family":"Uschner","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University of Bonn, Bonn, Germany"},{"name":"Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Schueller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelina","family":"Nikolova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University of Bonn, Bonn, Germany"},{"name":"Institute of Cellular Medicine, Fibrosis Research Group, Newcastle upon Tyne, United Kingdom"},{"name":"Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schierwagen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Magdaleno","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Gr\u00f6schl","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Loosen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ritz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Roderburg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vucur","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Twan","family":"Lammers","sequence":"additional","affiliation":[{"name":"Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University of Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Aachen, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonel","family":"Trebicka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University of Bonn, Bonn, Germany"},{"name":"Institute of Clinical Research, Odense University Hospital, University of Southern Denmark, Odense, Denmark"},{"name":"European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain"},{"name":"Institute for Bioengineering of Catalonia, Barcelona, Spain"},{"name":"Department of Internal Medicine I, University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"key":"2","doi-asserted-by":"crossref","first-page":"d808","DOI":"10.2741\/A813","article-title":"Activation of hepatic stellate cells--a key issue in liver fibrosis","volume":"7","author":"Friedman","year":"2002","journal-title":"Front Biosci"},{"key":"3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2010.03.021","article-title":"Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension","volume":"53","author":"Garc\u00eda-Pag\u00e1n","year":"2010","journal-title":"J Hepatol"},{"key":"4","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.jhep.2015.01.003","article-title":"Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments","volume":"62","author":"Shah","year":"2015","journal-title":"J Hepatol"},{"key":"5","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1053\/j.gastro.2008.03.007","article-title":"Portal hypertension and its complications","volume":"134","author":"Arroyo","year":"2008","journal-title":"Gastroenterology"},{"key":"6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","article-title":"EASL Clinical Practice Guidelines: Vascular diseases of the liver","volume":"64","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu","year":"2016","journal-title":"J Hepatol"},{"key":"7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jhep.2009.01.014","article-title":"Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis","volume":"50","author":"Matloff","year":"2009","journal-title":"J Hepatol"},{"key":"8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","volume":"50","author":"Bosch","year":"2009","journal-title":"J Hepatol"},{"key":"9","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","article-title":"Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study","volume":"49","author":"Bolondi","year":"2013","journal-title":"Eur J Cancer"},{"key":"10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Ross","year":"2017","journal-title":"Lancet"},{"key":"11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/labinvest.2010.148","article-title":"Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis","volume":"91","author":"Sauerbruch","year":"2011","journal-title":"Lab Invest"},{"key":"12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2009.06.024","article-title":"Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats","volume":"51","author":"Peck-Radosavljevic","year":"2009","journal-title":"J Hepatol"},{"key":"13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats","volume":"49","author":"Fernandez","year":"2009","journal-title":"Hepatology"},{"key":"14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2036.2011.04896.x","article-title":"The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study","volume":"35","author":"Peck-Radosavljevic","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1476-5381.2009.00158.x","article-title":"Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis","volume":"157","author":"Sauerbruch","year":"2009","journal-title":"Br J Pharmacol"},{"key":"16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Kelley","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Zopf","year":"2011","journal-title":"Int J Cancer"},{"key":"18","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1159\/000479732","article-title":"Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer","volume":"10","author":"Fonck","year":"2017","journal-title":"Case Rep Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Liegl-Atzwanger","year":"2016","journal-title":"Lancet Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/j.clcc.2017.09.004","article-title":"Clinical Features of Regorafenib-induced Liver Injury in Japanese Patients From Postmarketing Experience","volume":"17","author":"Takikawa","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"21","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/liv.13217","article-title":"Regorafenib induced severe toxic hepatitis: characterization and discussion","volume":"36","author":"Van den Eynde","year":"2016","journal-title":"Liver Int"},{"key":"22","doi-asserted-by":"publisher","first-page":"64136","DOI":"10.18632\/oncotarget.11636","article-title":"Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/cas.12907","article-title":"Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma","volume":"107","author":"Chayama","year":"2016","journal-title":"Cancer Sci"},{"key":"24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.12703\/P6-108","article-title":"Management of colorectal cancer","volume":"6","author":"Stintzing","year":"2014","journal-title":"F1000Prime Rep"},{"key":"25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Yoshino","year":"2013","journal-title":"Lancet"},{"key":"26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Cheng","year":"2015","journal-title":"Lancet Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/hep.22872","article-title":"Antiangiogenic therapy: not just for cancer anymore?","volume":"49","author":"Bruix","year":"2009","journal-title":"Hepatology"},{"key":"28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.dld.2017.11.001","article-title":"Clinical outcome of portal vein thrombosis in patients with digestive cancers: A large AGEO multicenter study","volume":"50","author":"Tougeron","year":"2018","journal-title":"Dig Liver Dis"},{"key":"29","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.thromres.2012.08.259","article-title":"Clinical approach to splanchnic vein thrombosis: risk factors and treatment","volume":"130","author":"Ageno","year":"2012","journal-title":"Thromb Res"},{"key":"30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jhep.2010.02.027","article-title":"New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis","volume":"53","author":"Jiang","year":"2010","journal-title":"J Hepatol"},{"key":"31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12876-015-0380-5","article-title":"Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats","volume":"15","author":"Chen","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"32","doi-asserted-by":"publisher","first-page":"894","DOI":"10.7150\/thno.21168","article-title":"Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development","volume":"8","author":"Ho","year":"2018","journal-title":"Theranostics"},{"key":"33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10620-012-2325-y","article-title":"Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo","volume":"58","author":"Friedman","year":"2013","journal-title":"Dig Dis Sci"},{"key":"34","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jpba.2018.07.039","article-title":"Metabolic profiling of the anti-tumor drug regorafenib in mice","volume":"159","author":"Li","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tox.2018.01.005","article-title":"Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells","volume":"395","author":"Kr\u00e4henb\u00fchl","year":"2018","journal-title":"Toxicology"},{"key":"36","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1002\/cncr.30863","article-title":"Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma","volume":"123","author":"Hutton","year":"2017","journal-title":"Cancer"},{"key":"37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/hep.21673","article-title":"Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase","volume":"46","author":"Heller","year":"2007","journal-title":"Hepatology"},{"key":"38","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/hep.23222","article-title":"Role of \u03b23-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis","volume":"50","author":"Sauerbruch","year":"2009","journal-title":"Hepatology"},{"key":"39","doi-asserted-by":"publisher","first-page":"G849","DOI":"10.1152\/ajpgi.00084.2009","article-title":"Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertension","volume":"297","author":"Endemann","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"40","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1172\/JCI7458","article-title":"Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility","volume":"104","author":"Groszmann","year":"1999","journal-title":"J Clin Invest"},{"key":"41","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1053\/j.gastro.2013.06.036","article-title":"Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis","volume":"145","author":"Trebicka","year":"2013","journal-title":"Gastroenterology"},{"key":"42","doi-asserted-by":"publisher","first-page":"e0162144","DOI":"10.1371\/journal.pone.0162144","article-title":"Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension","volume":"11","author":"Trebicka","year":"2016","journal-title":"PLoS One"},{"key":"43","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells","volume":"53","author":"Sauerbruch","year":"2010","journal-title":"J Hepatol"},{"key":"44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.23922","article-title":"Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis","volume":"53","author":"Luedde","year":"2011","journal-title":"Hepatology"},{"key":"45","doi-asserted-by":"publisher","first-page":"16552","DOI":"10.1038\/srep16552","article-title":"Activation of TGF-\u03b21-CD147 positive feedback loop in hepatic stellate cells promotes liver fibrosis","volume":"5","author":"Bian","year":"2015","journal-title":"Sci Rep"},{"key":"46","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.1073\/pnas.1507499112","article-title":"Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition","volume":"112","author":"Chen","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"47","doi-asserted-by":"publisher","first-page":"417023","DOI":"10.1155\/2015\/417023","article-title":"Isolation and time lapse microscopy of highly pure hepatic stellate cells","volume":"2015","author":"Tacke","year":"2015","journal-title":"Anal Cell Pathol (Amst)"},{"key":"48","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/labinvest.2012.106","article-title":"Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats","volume":"92","author":"Lammert","year":"2012","journal-title":"Lab Invest"},{"key":"49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ccell.2016.11.009","article-title":"RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer","volume":"31","author":"Luedde","year":"2017","journal-title":"Cancer Cell"},{"key":"50","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/liv.12627","article-title":"Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases","volume":"35","author":"Trautwein","year":"2015","journal-title":"Liver Int"},{"key":"51","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1478-3231.2011.02496.x","article-title":"Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts","volume":"31","author":"Zimmer","year":"2011","journal-title":"Liver Int"},{"key":"52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1755-1536-3-10","article-title":"Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosis","volume":"3","author":"Weiskirchen","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"key":"53","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/liv.12613","article-title":"Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension","volume":"25","author":"Krag","year":"2014","journal-title":"Liver Int"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T15:57:50Z","timestamp":1589039870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":53,"journal-issue":{"issue":"90","published-print":{"date-parts":[[2018,11,16]]}},"alternative-id":["26333","30546838"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.26333","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,16]]}}}